InMed Pharmaceuticals (INM) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
InMed Pharmaceuticals has made significant strides in its pharmaceutical programs, particularly with its Alzheimer’s treatment candidate, INM-901, showing promising preclinical data. The company also executed a reverse stock split to ensure continued compliance with Nasdaq listing requirements, reflecting its commitment to enhancing shareholder value.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.
